1.
Ali
MK
,
Bullard
KM
,
Saydah
S
,
Imperatore
G
,
Gregg
EW
.
Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014
.
Lancet Diabetes Endocrinol
2018
;
6
:
392
403
2.
Afkarian
M
,
Sachs
MC
,
Kestenbaum
B
, et al
Kidney disease and increased mortality risk in type 2 diabetes
.
J Am Soc Nephrol
2013
;
24
:
302
308
3.
Brenner
BM
,
Cooper
ME
,
de Zeeuw
D
, et al;
RENAAL Study Investigators
.
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
.
N Engl J Med
2001
;
345
:
861
869
4.
Lewis
EJ
,
Hunsicker
LG
,
Clarke
WR
, et al;
Collaborative Study Group
.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
.
N Engl J Med
2001
;
345
:
851
860
5.
Wanner
C
,
Inzucchi
SE
,
Lachin
JM
, et al;
EMPA-REG OUTCOME Investigators
.
Empagliflozin and progression of kidney disease in type 2 diabetes
.
N Engl J Med
2016
;
375
:
323
334
6.
Heerspink
HJL
,
Desai
M
,
Jardine
M
,
Balis
D
,
Meininger
G
,
Perkovic
V
.
Canagliflozin slows progression of renal function decline independently of glycemic effects
.
J Am Soc Nephrol
2017
;
28
:
368
375
7.
Marso
SP
,
Bain
SC
,
Consoli
A
, et al;
SUSTAIN-6 Investigators
.
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
.
N Engl J Med
2016
;
375
:
1834
1844
8.
Perkovic
V
,
Jardine
MJ
,
Neal
B
, et al;
CREDENCE Trial Investigators
.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
.
N Engl J Med
2019
;
380
:
2295
2306
9.
Bakris
GL
,
Agarwal
R
,
Anker
SD
, et al;
FIDELIO-DKD Investigators
.
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
.
N Engl J Med
2020
;
383
:
2219
2229
10.
White
KE
,
Bilous
RW
.
Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease
.
J Am Soc Nephrol
2000
;
11
:
1667
1673
11.
Sheetz
MJ
,
King
GL
.
Molecular understanding of hyperglycemia's adverse effects for diabetic complications
.
JAMA
2002
;
288
:
2579
2588
12.
Vallon
V
,
Komers
R
.
Pathophysiology of the diabetic kidney
.
Compr Physiol
2011
;
1
:
1175
1232
13.
Sorbinil Retinopathy Trial Research Group
.
A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy
.
Arch Ophthalmol
1990
;
108
:
1234
1244
14.
Schleicher
ED
,
Weigert
C
.
Role of the hexosamine biosynthetic pathway in diabetic nephropathy
.
Kidney Int Suppl
2000
;
77
:
S13
S18
15.
Tuttle
KR
,
Bakris
GL
,
Toto
RD
,
McGill
JB
,
Hu
K
,
Anderson
PW
.
The effect of ruboxistaurin on nephropathy in type 2 diabetes
.
Diabetes Care
2005
;
28
:
2686
2690
16.
Tonneijck
L
,
Muskiet
MH
,
Smits
MM
, et al
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
.
J Am Soc Nephrol
2017
;
28
:
1023
1039
17.
Brenner
BM
,
Lawler
EV
,
Mackenzie
HS
.
The hyperfiltration theory: a paradigm shift in nephrology
.
Kidney Int
1996
;
49
:
1774
1777
18.
Cooper
ME
,
Vranes
D
,
Youssef
S
, et al
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes
.
Diabetes
1999
;
48
:
2229
2239
19.
Gnudi
L
.
Angiopoietins and diabetic nephropathy
.
Diabetologia
2016
;
59
:
1616
1620
20.
Bohle
A
,
Wehrmann
M
,
Bogenschutz
O
,
Batz
C
,
Müller
CA
,
Müller
GA
.
The pathogenesis of chronic renal failure in diabetic nephropathy: investigation of 488 cases of diabetic glomerulosclerosis
.
Pathol Res Pract
1991
;
187
:
251
259
21.
Nguyen
D
,
Ping
F
,
Mu
W
,
Hill
P
,
Atkins
RC
,
Chadban
SJ
.
Macrophage accumulation in human progressive diabetic nephropathy
.
Nephrology (Carlton)
2006
;
11
:
226
231
22.
Yonemoto
S
,
Machiguchi
T
,
Nomura
K
,
Minakata
T
,
Nanno
M
,
Yoshida
H
.
Correlations of tissue macrophages and cytoskeletal protein expression with renal fibrosis in patients with diabetes mellitus
.
Clin Exp Nephrol
2006
;
10
:
186
192
23.
Tesch
GH
.
Macrophages and diabetic nephropathy
.
Semin Nephrol
2010
;
30
:
290
301
24.
Bertocchio
JP
,
Warnock
DG
,
Jaisser
F
.
Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease
.
Kidney Int
2011
;
79
:
1051
1060
25.
Yu
SM
,
Bonventre
JV
.
Acute kidney injury and progression of diabetic kidney disease
.
Adv Chronic Kidney Dis
2018
;
25
:
166
180
26.
Kinsey
GR
.
Macrophage dynamics in AKI to CKD progression
.
J Am Soc Nephrol
2014
;
25
:
209
211
27.
Barrera-Chimal
J
,
Estrela
GR
,
Lechner
SM
, et al
The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling
.
Kidney Int
2018
;
93
:
1344
1355
28.
Wang
Y
,
Harris
DC
.
Macrophages in renal disease
.
J Am Soc Nephrol
2011
; 
22
:
21
27
29.
Calle
P
,
Hotter
G
.
Macrophage phenotype and fibrosis in diabetic nephropathy
.
Int J Mol Sci
2020
;
21
:
2806
30.
Flyvbjerg
A
.
The role of the complement system in diabetic nephropathy
.
Nat Rev Nephrol
2017
;
13
:
311
318
31.
Østergaard
J
,
Thiel
S
,
Gadjeva
M
,
Hansen
TK
,
Rasch
R
,
Flyvbjerg
A
.
Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice
.
Diabetologia
2007
;
50
:
1541
1549
32.
Hansen
TK
,
Forsblom
C
,
Saraheimo
M
, et al
Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes
.
Diabetologia
2010
;
53
:
1517
1524
33.
Østergaard
JA
,
Thiel
S
,
Hovind
P
, et al
Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study
.
Diabetologia
2014
;
57
:
2201
2207
34.
Falk
RJ
,
Dalmasso
AP
,
Kim
Y
, et al
Neoantigen of the polymerized ninth component of complement: characterization of a monoclonal antibody and immunohistochemical localization in renal disease
.
J Clin Invest
1983
;
72
:
560
573
35.
Falk
RJ
,
Scheinman
JI
,
Mauer
SM
,
Michael
AF
.
Polyantigenic expansion of basement membrane constituents in diabetic nephropathy
.
Diabetes
1983
;
32
(
Suppl. 2
):
34
39
36.
Falk
RJ
,
Sisson
SP
,
Dalmasso
AP
,
Kim
Y
,
Michael
AF
,
Vernier
RL
.
Ultrastructural localization of the membrane attack complex of complement in human renal tissues
.
Am J Kidney Dis
1987
;
9
:
121
128
37.
Riser
BL
,
Denichilo
M
,
Cortes
P
, et al
Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis
.
J Am Soc Nephrol
2000
;
11
:
25
38
38.
Tervaert
TW
,
Mooyaart
AL
,
Amann
K
, et al
Pathologic classification of diabetic nephropathy
.
J Am Soc Nephrol
2010
;
21
:
556
563
39.
Perrin
NE
,
Torbjörnsdotter
TB
,
Jaremko
GA
,
Berg
UB
.
Follow-up of kidney biopsies in normoalbuminuric patients with type 1 diabetes
.
Pediatr Nephrol
2004
;
19
:
1004
1013
40.
Drummond
K
,
Mauer
M
;
International Diabetic Nephropathy Study Group
.
The early natural history of nephropathy in type 1 diabetes: II. early renal structural changes in type 1 diabetes
.
Diabetes
2002
;
51
:
1580
1587
41.
Kim
Y
,
Kleppel
MM
,
Butkowski
R
,
Mauer
SM
,
Wieslander
J
,
Michael
AF
.
Differential expression of basement membrane collagen chains in diabetic nephropathy
.
Am J Pathol
1991
;
138
:
413
420
42.
Dominguez
JH
,
Tang
N
,
Xu
W
, et al
Studies of renal injury III: lipid-induced nephropathy in type II diabetes
.
Kidney Int
2000
;
57
:
92
104
43.
Stratton
IM
,
Adler
AI
,
Neil
HA
, et al
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
.
BMJ
2000
;
321
:
405
412
44.
Rossing
K
,
Christensen
PK
,
Hovind
P
,
Tarnow
L
,
Rossing
P
,
Parving
H-H
.
Progression of nephropathy in type 2 diabetic patients
.
Kidney Int
2004
;
66
:
1596
1605
45.
UK Prospective Diabetes Study Group
.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
.
Lancet
1998
;
352
:
837
853
46.
Holman
RR
,
Paul
SK
,
Bethel
MA
,
Matthews
DR
,
Neil
HA
.
10-year follow-up of intensive glucose control in type 2 diabetes
.
N Engl J Med
2008
;
359
:
1577
1589
47.
Curovic
VR
,
Theilade
S
,
Winther
SA
, et al
Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes
.
Diabet Med
.
Online ahead of print on 11 November 2020 (doi: 10.1111/dme.14459)
48.
Hsu
CC
,
Chang
HY
,
Huang
MC
, et al
HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study
.
Diabetologia
2012
;
55
:
3163
3172
49.
ADVANCE Collaborative Group
;
Patel
A
,
MacMahon
S
,
Chalmers
J
, et al
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
.
N Engl J Med
2008
;
358
:
2560
2572
50.
Perkovic
V
,
Heerspink
HL
,
Chalmers
J
, et al;
ADVANCE Collaborative Group
.
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
.
Kidney Int
2013
;
83
:
517
523
51.
Mann
JFE
,
Ørsted
DD
,
Brown-Frandsen
K
, et al;
LEADER Steering Committee and Investigators
.
Liraglutide and renal outcomes in type 2 diabetes
.
N Engl J Med
2017
;
377
:
839
848
52.
Gerstein
HC
,
Colhoun
HM
,
Dagenais
GR
, et al;
REWIND Investigators
.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
.
Lancet
2019
;
394
:
131
138
53.
Heerspink
HJL
,
Stefánsson
BV
,
Correa-Rotter
R
, et al.
DAPA-CKD Trial Committees and Investigators
.
Dapagliflozin in patients with chronic kidney disease
.
N Engl J Med
2020
;
383
:
1436
1446
54.
Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications
.
J Hypertens
1993
;
11
:
309
317
55.
Retnakaran
R
,
Cull
CA
,
Thorne
KI
,
Adler
AI
,
Holman
RR
;
UKPDS Study Group
.
Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74
.
Diabetes
2006
;
55
:
1832
1839
56.
Nørgaard
K
,
Feldt-Rasmussen
B
,
Borch-Johnsen
K
,
Saelan
H
,
Deckert
T
.
Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus
.
Diabetologia
1990
;
33
:
407
410
57.
McMullan
CJ
,
Heerspink
HJL
,
Parving
H-H
,
Dwyer
JP
,
Forman
JP
,
de Zeeuw
D
.
Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial
.
Am J Kidney Dis
2014
;
64
:
714
722
58.
Parving
H-H
,
Lehnert
H
,
Brochner-Mortensen
J
,
Gomis
R
,
Andersen
S
,
Arner
P
.
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
.
N Engl J Med
2001
;
345
:
870
878
59.
Persson
F
,
Lindhardt
M
,
Rossing
P
,
Parving
H-H
.
Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: a systematic review
.
J Renin Angiotensin Aldosterone Syst
2016
;
17
:
1470320316652047
60.
Peti-Peterdi
J
.
High glucose and renin release: the role of succinate and GPR91
.
Kidney Int
2010
;
78
:
1214
1217
61.
Frimodt-Moller
M
,
Persson
F
,
Rossing
P
.
Mitigating risk of aldosterone in diabetic kidney disease
.
Curr Opin Nephrol Hypertens
2020
;
29
:
145
151
62.
Hsu
CY
,
McCulloch
CE
,
Iribarren
C
,
Darbinian
J
,
Go
AS
.
Body mass index and risk for end-stage renal disease
.
Ann Intern Med
2006
;
144
:
21
28
63.
Krikken
JA
,
Bakker
SJ
,
Navis
GJ
.
Role of renal haemodynamics in the renal risks of overweight
.
Nephrol Dial Transplant
2009
;
24
:
1708
1711
64.
Sharma
K
.
The link between obesity and albuminuria: adiponectin and podocyte dysfunction
.
Kidney Int
2009
;
76
:
145
148
65.
Bjornstad
P
,
Nehus
E
,
Jenkins
T
, et al
Five-year kidney outcomes of bariatric surgery differ in severely obese adolescents and adults with and without type 2 diabetes
.
Kidney Int
2020
;
97
:
995
1005
66.
Scirica
BM
,
Bohula
EA
,
Dwyer
JP
, et al;
CAMELLIA-TIMI 61 Steering Committee and Investigators
.
Lorcaserin and renal outcomes in obese and overweight patients in the CAMELLIA-TIMI 61 trial
.
Circulation
2019
;
139
:
366
375
67.
von Scholten
BJ
,
Persson
F
,
Svane
MS
,
Hansen
TW
,
Madsbad
S
,
Rossing
P
.
Effect of large weight reductions on measured and estimated kidney function
.
BMC Nephrol
2017
;
18
:
52
68.
Daousi
C
,
Bain
SC
,
Barnett
AH
,
Gill
GV
.
Hypertriglyceridaemia is associated with an increased likelihood of albuminuria in extreme duration (> 50 years) type 1 diabetes
.
Diabet Med
2008
;
25
:
1234
1236
69.
Hovind
P
,
Rossing
P
,
Tarnow
L
,
Smidt
UM
,
Parving
H-H
.
Progression of diabetic nephropathy
.
Kidney Int
2001
;
59
:
702
709
70.
Thomas
MC
,
Rosengard-Barlund
M
,
Mills
V
, et al
Serum lipids and the progression of nephropathy in type 1 diabetes
.
Diabetes Care
2006
;
29
:
317
322
71.
Tolonen
N
,
Forsblom
C
,
Thorn
L
, et al;
FinnDiane Study Group
.
Relationship between lipid profiles and kidney function in patients with type 1 diabetes
.
Diabetologia
2008
;
51
:
12
20
72.
Tofte
N
,
Suvitaival
T
,
Ahonen
L
, et al
Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes
.
Sci Rep
2019
;
9
:
16398
73.
Hsu
CC
,
Chang
HY
,
Huang
MC
, et al
Association between insulin resistance and development of microalbuminuria in type 2 diabetes: a prospective cohort study
.
Diabetes Care
2011
;
34
:
982
987
74.
Thorn
LM
,
Forsblom
C
,
Waden
J
, et al;
Finnish Diabetic Nephropathy (FinnDiane) Study Group
.
Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes
.
Diabetes Care
2009
;
32
:
950
952
75.
Kilpatrick
ES
,
Rigby
AS
,
Atkin
SL
.
Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial
.
Diabetes Care
2007
;
30
:
707
712
76.
Metascreen Writing Committee
;
Bonadonna
RC
,
Cucinotta
D
,
Fedele
D
,
Riccardi
G
,
Tiengo
A
.
The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey
.
Diabetes Care
2006
;
29
:
2701
2707
77.
Oellgaard
J
,
Gaede
P
,
Rossing
P
,
Persson
F
,
Parving
H-H
,
Pedersen
O
.
Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits
.
Kidney Int
2017
;
91
:
982
988
78.
Sandholm
N
,
Van Zuydam
N
,
Ahlqvist
E
, et al,
The FinnDiane Study Group
;
Tuomilehto
J
,
Lyssenko
V
,
McKeigue
PM
, et al,
The DCCT/EDIC Study Group
;
Florez
JC
,
Hirschhorn
JN
,
Maxwell
AP
,
GENIE Consortium
;
Dunger
D
,
Cobelli
C
,
Colhoun
HM
, et al,
SUMMIT Consortium
.
The genetic landscape of renal complications in type 1 diabetes
.
J Am Soc Nephrol
2017
;
28
:
557
574
79.
van Zuydam
NR
,
Ahlqvist
E
,
Sandholm
N
, et al
A genome-wide association study of diabetic kidney disease in subjects with type 2 diabetes
.
Diabetes
2018
;
67
:
1414
1427
80.
Seaquist
ER
,
Goetz
FC
,
Rich
S
,
Barbosa
J
.
Familial clustering of diabetic kidney disease: evidence of genetic susceptibility to diabetic nephropathy
.
N Engl J Med
1989
;
320
:
1161
1165
81.
Imperatore
G
,
Nelson
RG
.
Genetic susceptibility to nephropathy in Pima Indians with type 2 diabetes mellitus
.
Nephrology
1998
;
4
(
Suppl. 2
):
S34
S39
82.
Fagerudd
JA
,
Tarnow
L
,
Jacobsen
P
, et al
Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients
.
Diabetes
1998
;
47
:
439
444
83.
Thorn
LM
,
Forsblom
C
,
Fagerudd
J
,
Pettersson-Fernholm
K
,
Kilpikari
R
,
Groop
P-H
;
FinnDiane Study Group
.
Clustering of risk factors in parents of patients with type 1 diabetes and nephropathy
.
Diabetes Care
2007
;
30
:
1162
1167
84.
Wuttke
M
,
Li
Y
,
Li
M
, et al
A catalog of genetic loci associated with kidney function from analyses of a million individuals
.
Nat Genet
2019
;
51
:
957
972
85.
Keating
ST
,
van Diepen
JA
,
Riksen
NP
,
El-Osta
A
.
Epigenetics in diabetic nephropathy, immunity and metabolism
.
Diabetologia
2018
;
61
:
6
20
86.
Allawi
J
,
Rao
PV
,
Gilbert
R
, et al
Microalbuminuria in non-insulin-dependent diabetes: its prevalence in Indian compared with Europid patients
.
Br Med J (Clin Res Ed)
1988
;
296
:
462
464
87.
Dreyer
G
,
Hull
S
,
Aitken
Z
,
Chesser
A
,
Yaqoob
MM
.
The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease
.
QJM
2009
;
102
:
261
269
88.
Sinha
SK
,
Shaheen
M
,
Rajavashisth
TB
,
Pan
D
,
Norris
KC
,
Nicholas
SB
.
Association of race/ethnicity, inflammation, and albuminuria in patients with diabetes and early chronic kidney disease
.
Diabetes Care
2014
;
37
:
1060
1068
89.
Nelson
RG
,
Knowler
WC
,
Pettitt
DJ
,
Hanson
RL
,
Bennett
PH
.
Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM
.
Diabetes Care
1995
;
18
:
182
187
90.
Joshy
G
,
Dunn
P
,
Fisher
M
,
Lawrenson
R
.
Ethnic differences in the natural progression of nephropathy among diabetes patients in New Zealand: hospital admission rate for renal complications, and incidence of end-stage renal disease and renal death
.
Diabetologia
2009
;
52
:
1474
1478
91.
Collins
VR
,
Dowse
GK
,
Finch
CF
,
Zimmet
PZ
,
Linnane
AW
.
Prevalence and risk factors for micro- and macroalbuminuria in diabetic subjects and entire population of Nauru
.
Diabetes
1989
;
38
:
1602
1610
92.
TODAY Study Group
.
Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial
.
Diabetes Care
2013
;
36
:
1735
1741
93.
Dart
AB
,
Sellers
EA
,
Martens
PJ
,
Rigatto
C
,
Brownell
MD
,
Dean
HJ
.
High burden of kidney disease in youth-onset type 2 diabetes
.
Diabetes Care
2012
;
35
:
1265
1271
94.
Dyck
RF
,
Jiang
Y
,
Osgood
ND
.
The long-term risks of end stage renal disease and mortality among First Nations and non-First Nations people with youth-onset diabetes
.
Can J Diabetes
2014
;
38
:
237
243
95.
Chan
JC
,
Lau
ES
,
Luk
AO
, et al
Premature mortality and comorbidities in young-onset diabetes: a 7-year prospective analysis
.
Am J Med
2014
;
127
:
616
624
96.
Sellers
EA
,
Blydt-Hansen
TD
,
Dean
HJ
,
Gibson
IW
,
Birk
PE
,
Ogborn
M
.
Macroalbuminuria and renal pathology in First Nation youth with type 2 diabetes
.
Diabetes Care
2009
;
32
:
786
790
97.
Murussi
M
,
Campagnolo
N
,
Beck
MO
,
Gross
JL
,
Silveiro
SP
.
High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian type 2 diabetic patients: an 8-year follow-up study
.
Diabet Med
2007
;
24
:
1136
1142
98.
Rossing
P
,
Hougaard
P
,
Parving
H-H
.
Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study
.
Diabetes Care
2002
;
25
:
859
864
99.
de Zeeuw
D
,
Ramjit
D
,
Zhang
Z
, et al
Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL
.
Kidney Int
2006
;
69
:
1675
1682
100.
Babazono
T
,
Nyumura
I
,
Toya
K
, et al
Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients
.
Diabetes Care
2009
;
32
:
1518
1520
101.
Zoppini
G
,
Targher
G
,
Chonchol
M
, et al
Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function
.
Clin J Am Soc Nephrol
2012
;
7
:
401
408
102.
Rossing
P
,
Hommel
E
,
Smidt
UM
,
Parving
H-H
.
Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment
.
Diabetologia
1994
;
37
:
511
516
103.
Heerspink
HJL
,
Greene
T
,
Tighiouart
H
, et al;
Chronic Kidney Disease Epidemiology Collaboration
.
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
.
Lancet Diabetes Endocrinol
2019
;
7
:
128
139
104.
Gordin
D
,
Hiilesmaa
V
,
Fagerudd
J
, et al;
FinnDiane Study Group
.
Preeclampsia but not pregnancy-induced hypertension is a risk factor for diabetic nephropathy in type 1 diabetic women
.
Diabetologia
2007
;
50
:
516
522
105.
Shultis
WA
,
Weil
EJ
,
Looker
HC
, et al
Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes
.
Diabetes Care
2007
;
30
:
306
311
106.
Tahrani
AA
,
Ali
A
,
Raymond
NT
, et al
Obstructive sleep apnea and diabetic nephropathy: a cohort study
.
Diabetes Care
2013
;
36
:
3718
3725
107.
Targher
G
,
Bertolini
L
,
Rodella
S
, et al
Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients
.
Diabetologia
2008
;
51
:
444
450
108.
Targher
G
,
Mantovani
A
,
Pichiri
I
, et al
Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes
.
Diabetes Care
2014
;
37
:
1729
1736
109.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
.
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease
.
Kidney Int Suppl
2013
;
3
:
1
150
110.
Rossing
P
,
Persson
F
,
Frimodt-Moller
M
,
Hansen
TW
.
Linking kidney and cardiovascular complications in diabetes: impact on prognostication and treatment: the 2019 Edwin Bierman Award Lecture
.
Diabetes
2021
;
70
:
39
50
111.
de Zeeuw
D
,
Remuzzi
G
,
Parving
H-H
, et al
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
.
Circulation
2004
;
110
:
921
927
112.
Coresh
J
,
Heerspink
HJL
,
Sang
Y
, et al;
Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration
.
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
.
Lancet Diabetes Endocrinol
2019
;
7
:
115
127
113.
Desai
AS
,
Toto
R
,
Jarolim
P
, et al
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD
.
Am J Kidney Dis
2011
;
58
:
717
728
114.
Galsgaard
J
,
Persson
F
,
Hansen
TW
, et al
Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy
.
Kidney Int
2017
;
92
:
1242
1248
115.
Good
DM
,
Zurbig
P
,
Argiles
A
, et al
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease
.
Mol Cell Proteomics
2010
;
9
:
2424
2437
116.
Zurbig
P
,
Jerums
G
,
Hovind
P
, et al
Urinary proteomics for early diagnosis in diabetic nephropathy
.
Diabetes
2012
;
61
:
3304
3313
117.
Tofte
N
,
Lindhardt
M
,
Adamova
K
, et al;
PRIORITY Investigators
.
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
.
Lancet Diabetes Endocrinol
2020
;
8
:
301
312
118.
Amdur
RL
,
Feldman
HI
,
Gupta
J
, et al;
CRIC Study Investigators
.
Inflammation and progression of CKD: the CRIC study
.
Clin J Am Soc Nephrol
2016
;
11
:
1546
1556
119.
Niewczas
MA
,
Pavkov
ME
,
Skupien
J
, et al
A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes
.
Nat Med
2019
;
25
:
805
813
120.
Pilemann-Lyberg
S
,
Hansen
TW
,
Tofte
N
, et al
Uric acid is an independent risk factor for decline in kidney function, cardiovascular events, and mortality in patients with type 1 diabetes
.
Diabetes Care
2019
;
42
:
1088
1094
121.
Doria
A
,
Galecki
AT
,
Spino
C
, et al;
PERL Study Group
.
Serum urate lowering with allopurinol and kidney function in type 1 diabetes
.
N Engl J Med
2020
;
382
:
2493
2503
122.
Ahola
AJ
,
Sandholm
N
,
Forsblom
C
,
Harjutsalo
V
,
Dahlstrom
E
,
Groop
P-H
;
FinnDiane Study Group
.
The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes
.
Kidney Int
2017
;
91
:
1178
1185
123.
Stack
AG
,
Dronamraju
N
,
Parkinson
J
, et al
Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: a randomized trial
.
Am J Kidney Dis
2021
;
77
:
481
489
124.
Kjaer
LK
,
Cejvanovic
V
,
Henriksen
T
, et al
Cardiovascular and all-cause mortality risk associated with urinary excretion of 8-oxoGuo, a biomarker for RNA oxidation, in patients with type 2 diabetes: a prospective cohort study
.
Diabetes Care
2017
;
40
:
1771
1778
125.
Komorowsky
CV
,
Brosius
FC
 III
,
Pennathur
S
,
Kretzler
M
.
Perspectives on systems biology applications in diabetic kidney disease
.
J Cardiovasc Transl Res
2012
;
5
:
491
508
126.
Brosius
FC
,
Tuttle
KR
,
Kretzler
M
.
JAK inhibition in the treatment of diabetic kidney disease
.
Diabetologia
2016
;
59
:
1624
1627
127.
Pena
MJ
,
Heerspink
HJL
,
Hellemons
ME
, et al
Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with type 2 diabetes mellitus
.
Diabet Med
2014
;
31
:
1138
1147
128.
Solini
A
,
Manca
ML
,
Penno
G
,
Pugliese
G
,
Cobb
JE
,
Ferrannini
E
.
Prediction of declining renal function and albuminuria in patients with type 2 diabetes by metabolomics
.
J Clin Endocrinol Metab
2016
;
101
:
696
704
129.
Sharma
K
,
Karl
B
,
Mathew
AV
, et al
Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease
.
J Am Soc Nephrol
2013
;
24
:
1901
1912
130.
Niewczas
MA
,
Sirich
TL
,
Mathew
AV
, et al
Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study
.
Kidney Int
2014
;
85
:
1214
1224
131.
Tofte
N
,
Suvitaival
T
,
Trost
K
, et al
Metabolomic assessment reveals alteration in polyols and branched chain amino acids associated with present and future renal impairment in a discovery cohort of 637 persons with type 1 diabetes
.
Front Endocrinol (Lausanne)
2019
;
10
:
818
132.
Parving
H-H
,
Mauer
M
,
Fioretto
P
,
Rossing
P
,
Ritz
E
. Diabetic nephropathy. In
Brenner and Rector's the Kidney
. 9th ed.
Taal
MW
,
Chertow
GM
,
Marsden
PA
,
Skorecki
K
,
Yu
ASL
,
Brenner
BM
, Eds.
Philadelphia, PA
,
Elsevier
,
2012
, p.
1411
1454
133.
Perkins
BA
,
Ficociello
LH
,
Silva
KH
,
Finkelstein
DM
,
Warram
JH
,
Krolewski
AS
.
Regression of microalbuminuria in type 1 diabetes
.
N Engl J Med
2003
;
348
:
2285
2293
134.
Hovind
P
,
Tarnow
L
,
Rossing
P
, et al
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study
.
BMJ
2004
;
328
:
1105
135.
Gaede
P
,
Tarnow
L
,
Vedel
P
,
Parving
H-H
,
Pedersen
O
.
Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria
.
Nephrol Dial Transplant
2004
;
19
:
2784
2788
136.
Solini
A
,
Penno
G
,
Bonora
E
, et al;
Renal Insufficiency And Cardiovascular Events (RIACE) Study Group
.
Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study
2012
;
35
:
143
149
137.
Critselis
E
,
Vlahou
A
,
Stel
VS
,
Morton
RL
.
Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion
.
Nephrol Dial Transplant
2018
;
33
:
441
449
138.
Tuttle
KR
,
Alicic
RZ
,
Duru
OK
, et al
Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry
.
JAMA Netw Open
2019
;
2
:
e1918169
139.
Khan
MAB
,
Hashim
MJ
,
King
JK
,
Govender
RD
,
Mustafa
H
,
Al Kaabi
J
.
Epidemiology of type 2 diabetes: global burden of disease and forecasted trends
.
J Epidemiol Glob Health
2020
;
10
:
107
111
140.
Whaley-Connell
A
,
Sowers
JR
.
Basic science: pathophysiology: the cardiorenal metabolic syndrome
.
J Am Soc Hypertens
2014
;
8
:
604
606
141.
Arnold
SV
,
Kosiborod
M
,
Wang
J
,
Fenici
P
,
Gannedahl
G
,
LoCasale
RJ
.
Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry
.
Diabetes Obes Metab
2018
;
20
:
2000
2003
142.
Ronco
C
,
Haapio
M
,
House
AA
,
Anavekar
N
,
Bellomo
R
.
Cardiorenal syndrome
.
J Am Coll Cardiol
2008
;
52
:
1527
1539
143.
Dokken
BB
.
The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids
.
Diabetes Spectr
2008
;
21
:
160
165
144.
Kannel
WB
,
McGee
DL
.
Diabetes and cardiovascular disease: the Framingham study
.
JAMA
1979
;
241
:
2035
2038
145.
Gore
MO
,
Patel
MJ
,
Kosiborod
M
, et al;
National Registry of Myocardial Infarction Investigators
.
Diabetes mellitus and trends in hospital survival after myocardial infarction, 1994 to 2006
.
Circ Cardiovasc Qual Outcomes
2012
;
5
:
791
797
146.
Petrie
JR
,
Guzik
TJ
,
Touyz
RM
.
Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms
.
Can J Cardiol
2018
;
34
:
575
584
147.
Grisanti
LA
.
Diabetes and arrhythmias: pathophysiology, mechanisms and therapeutic outcomes
.
Front Physiol
2018
;
9
:
1669
148.
Nichols
GA
,
Hillier
TA
,
Erbey
JR
,
Brown
JB
.
Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors
.
Diabetes Care
2001
;
24
:
1614
1619
149.
Meagher
P
,
Adam
M
,
Civitarese
R
,
Bugyei-Twum
A
,
Connelly
KA
.
Heart failure with preserved ejection fraction in diabetes: mechanisms and management
.
Can J Cardiol
2018
;
34
:
632
643
150.
Jia
G
,
Hill
MA
,
Sowers
JR
.
Diabetic cardiomyopathy
.
Circ Res
2018
;
122
:
624
638
151.
Kenny
HC
,
Abel
ED
.
Heart failure in type 2 diabetes mellitus
.
Circ Res
2019
; 
124
:
121
141
152.
Jensen
MT
,
Fung
K
,
Aung
N
, et al
Changes in cardiac morphology and function in individuals with diabetes mellitus
.
Circ Cardiovasc Imaging
2019
;
12
:
e009476
153.
Gheith
O
,
Farouk
N
,
Nampoory
N
,
Halim
MA
,
Al-Otaibi
T
.
Diabetic kidney disease: world wide difference of prevalence and risk factors
.
J Nephropharmacol
2016
;
5
:
49
56
154.
Piccoli
GB
,
Grassi
G
,
Cabiddu
G
, et al
Diabetic kidney disease: a syndrome rather than a single disease
.
Rev Diabet Stud
2015
;
12
:
87
109
155.
Brown
JM
,
Everett
BM
.
Cardioprotective diabetes drugs: what cardiologists need to know
.
Cardiovasc Endocrinol Metab
2019
;
8
:
96
105
156.
McGuire
DK
,
Shih
WJ
,
Cosentino
F
, et al
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
.
JAMA Cardiol
2021
;
6
:
148
158
157.
American Diabetes Association
.
10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes—2021
.
Diabetes Care
2021
;
44
(
Suppl. 1
):
S125
S150
158.
Pugliese
G
,
Penno
G
,
Natali
A
, et al;
Italian Diabetes Society; Italian Society of Nephrology
.
Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function.”
.
J Nephrol
2020
;
33
:
9
35
159.
Wiviott
SD
,
Raz
I
,
Bonaca
MP
, et al;
DECLARE–TIMI 58 Investigators
.
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
.
N Engl J Med
2019
;
380
:
347
357
160.
Mosenzon
O
,
Wiviott
SD
,
Cahn
A
, et al
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
.
Lancet Diabetes Endocrinol
2019
;
7
:
606
617
161.
Neal
B
,
Perkovic
V
,
Mahaffey
KW
, et al;
CANVAS Program Collaborative Group
.
Canagliflozin and cardiovascular and renal events in type 2 diabetes
.
N Engl J Med
2017
;
377
:
644
657
162.
Neuen
BL
,
Young
T
,
Heerspink
HJL
, et al
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
.
Lancet Diabetes Endocrinol
2019
;
7
:
845
854
162a.
U.S. Food and Drug Administration
.
FDA approves treatment for chronic kidney disease: approval is first to cover many causes of disease
.
163.
Pitt
B
,
Pfeffer
MA
,
Assmann
SF
, et al;
TOPCAT Investigators
.
Spironolactone for heart failure with preserved ejection fraction
.
N Engl J Med
2014
;
370
:
1383
1392
164.
de Denus
S
,
O'Meara
E
,
Desai
AS
, et al
Spironolactone metabolites in TOPCAT: new insights into regional variation
.
N Engl J Med
2017
;
376
:
1690
1692
165.
Alicic
RZ
,
Rooney
MT
,
Tuttle
KR
.
Diabetic kidney disease: challenges, progress, and possibilities
.
Clin J Am Soc Nephrol
2017
;
12
:
2032
2045
166.
Centers for Disease Control and Prevention
.
National Diabetes Statistics Report, 2020
.
Atlanta, GA
,
Centers for Disease Control and Prevention, U.S. Department of Health and Human Services
,
2020
167.
Tuttle
KR
,
Bakris
GL
,
Bilous
RW
, et al
Diabetic kidney disease: a report from an ADA consensus conference
.
Am J Kidney Dis
2014
;
64
:
510
533
168.
American Diabetes Association
.
11. Microvascular complications and foot care: Standards of Medical Care in Diabetes—2021
.
Diabetes Care
2021
;
44
(
Suppl. 1
):
S151
S167
169.
Shlipak
MG
,
Tummalapalli
SL
,
Boulware
LE
, et al;
Conference Participants
.
The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference
.
Kidney Int
2021
;
99
:
34
47
170.
Nolte
E
,
McKee
M
.
Variations in amenable mortality: trends in 16 high-income nations
.
Health Policy
2011
;
103
:
47
52
171.
Schroeder
SA
.
Shattuck Lecture. We can do better: improving the health of the American people
.
N Engl J Med
2007
;
357
:
1221
1228
172.
Hall
YN
.
Social determinants of health: addressing unmet needs in nephrology
.
Am J Kidney Dis
2018
;
72
:
582
591
173.
Norton
JM
,
Moxey-Mims
MM
,
Eggers
PW
, et al
Social determinants of racial disparities in CKD
.
J Am Soc Nephrol
2016
;
27
:
2576
2595
174.
Nicholas
SB
,
Kalantar-Zadeh
K
,
Norris
KC
.
Socioeconomic disparities in chronic kidney disease
.
Adv Chronic Kidney Dis
2015
;
22
:
6
15
175.
Bailey
ZD
,
Feldman
JM
,
Bassett
MT
.
How structural racism works: racist policies as a root cause of U.S. racial health inequities
.
N Engl J Med
2021
;
384
:
768
773
176.
Bailey
ZD
,
Krieger
N
,
Agénor
M
,
Graves
J
,
Linos
N
,
Bassett
MT
.
Structural racism and health inequities in the USA: evidence and interventions
.
Lancet
2017
;
389
:
1453
1463
177.
Moosa
MR
,
Norris
KC
.
Sustainable social development: tackling poverty to achieve kidney health equity
.
Nat Rev Nephrol
2021
;
17
:
3
4
178.
Laster
M
,
Shen
JI
,
Norris
KC
.
Kidney disease among African Americans: a population perspective
.
Am J Kidney Dis
2018
;
72
(
Suppl. 1
):
S3
S7
179.
Crews
DC
,
Pfaff
T
,
Powe
NR
.
Socioeconomic factors and racial disparities in kidney disease outcomes
.
Semin Nephrol
2013
;
33
:
468
475
180.
Geronimus
AT
,
Hicken
M
,
Keene
D
,
Bound
J
.
“Weathering” and age patterns of allostatic load scores among Blacks and Whites in the United States
.
Am J Public Health
2006
;
96
:
826
833
181.
Marmot
M
,
Friel
S
,
Bell
R
,
Houweling
TA
,
Taylor
S
;
Commission on Social Determinants of Health
.
Closing the gap in a generation: health equity through action on the social determinants of health
.
Lancet
2008
;
372
:
1661
1669
182.
Wen
M
,
Browning
CR
,
Cagney
KA
.
Poverty, affluence, and income inequality: neighborhood economic structure and its implications for health
.
Soc Sci Med
2003
;
57
:
843
860
183.
Payne
RK
,
Blair
T
.
A Framework for Understanding Poverty.
Highlands, TX
,
aha! Process
,
2005
.
184.
Duru
OK
,
Middleton
T
,
Tewari
MK
,
Norris
K
.
The Landscape of diabetic kidney disease in the United States
.
Curr Diab Rep
2018
;
18
:
14
185.
De la Fuente
F
,
Saldías
MA
,
Cubillos
C
, et al
Green space exposure association with type 2 diabetes mellitus, physical activity, and obesity: a systematic review
.
Int J Environ Res Public Health
2020
;
18
:
97
186.
Eberly
LA
,
Yang
L
,
Eneanya
ND
, et al
Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US
.
JAMA Netw Open
2021
;
4
:
e216139
187.
Oppenheimer
GM
.
Paradigm lost: race, ethnicity, and the search for a new population taxonomy
.
Am J Public Health
2001
;
91
:
1049
1055
188.
Genovese
G
,
Friedman
DJ
,
Ross
,
MD
, et al
Association of trypanolytic ApoL1 variants with kidney disease in African Americans
.
Science
2010
;
329
:
841
845
189.
Umeukeje
EM
,
Young
BA
.
Genetics and ESKD disparities in African Americans
.
Am J Kidney Dis
2019
;
74
:
811
821
190.
Gutiérrez
OM
,
Irvin
MR
,
Chaudhary
NS
, et al
APOL1 nephropathy risk variants and incident cardiovascular disease events in community-dwelling Black adults
.
Circ Genom Precis Med
2018
;
11
:
e002098
191.
Palmer
ND
,
Freedman
BI
.
APOL1 and progression of nondiabetic nephropathy
.
J Am Soc Nephrol
2013
;
24
:
1344
1346
192.
Levey
AS
,
Bosch
JP
,
Lewis
JB
,
Greene
T
,
Rogers
N
,
Roth
D
.
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group
.
Ann Intern Med
1999
;
130
:
461
470
193.
Levey
AS
,
Stevens
LA
,
Schmid
CH
, et al;
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
.
A new equation to estimate glomerular filtration rate
.
Ann Intern Med
2009
;
150
:
604
612
194.
Norris
KC
,
Eneanya
ND
,
Boulware
LE
.
Removal of race from estimates of kidney function: first, do no harm
.
JAMA
2021
;
325
:
135
137
195.
Subramanian
SV
,
Jones
K
,
Kaddour
A
,
Krieger
N
.
Revisiting Robinson: the perils of individualistic and ecologic fallacy
.
Int J Epidemiol
2009
;
38
:
342–360; author reply 370
373
196.
American Diabetes Association
.
1. Improving care and promoting health in populations: Standards of Medical Care in Diabetes—2021
.
Diabetes Care
2021
;
44
(
Suppl. 1
):
S7
S14
197.
Pagels
AA
,
Hylander
B
,
Alvarsson
M
.
A multi-dimensional support programme for patients with diabetic kidney disease
.
J Ren Care
2015
;
41
:
187
194
198.
Tuot
DS
,
Diamantidis
CJ
,
Corbett
CF
, et al
The last mile: translational research to improve CKD outcomes
.
Clin J Am Soc Nephrol
2014
;
9
:
1802
1805
199.
Narva
AS
,
Norton
JM
,
Boulware
LE
.
Educating patients about CKD: the path to self-management and patient-centered care
.
Clin J Am Soc Nephrol
2016
;
11
:
694
703
200.
Goldstein
K
,
Briggs
M
,
Oleynik
V
, et al
Using digital media to promote kidney disease education
.
Adv Chronic Kidney Dis
2013
;
20
:
364
369
201.
Tuttle
KR
,
Bakris
GL
,
Bilous
RW
, et al
Diabetic kidney disease: a report from an ADA consensus conference
.
Diabetes Care
2014
;
37
:
2864
2883
202.
Afkarian
M
,
Zelnick
LR
,
Hall
YN
, et al
Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014
.
JAMA
2016
;
316
:
602
610
203.
de Boer
IH
,
Rue
TC
,
Hall
YN
,
Heagerty
PJ
,
Weiss
NS
,
Himmelfarb
J
.
Temporal trends in the prevalence of diabetic kidney disease in the United States
.
JAMA
2011
;
305
:
2532
2539
204.
de Boer
IH
;
DCCT/EDIC Research Group
.
Kidney disease and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study
.
Diabetes Care
2014
;
37
:
24
30
205.
Brannick
B
,
Wynn
A
,
Dagogo-Jack
S
.
Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications
.
Exp Biol Med (Maywood)
2016
;
241
:
1323
1331
206.
Plantinga
LC
,
Crews
DC
,
Coresh
J
, et al;
CDC CKD Surveillance Team
.
Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes
.
Clin J Am Soc Nephrol
2010
;
5
:
673
682
207.
United States Renal Data System
.
Annual Data Report: Epidemiology of Kidney Disease in the United States
.
Bethesda, MD
,
National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
,
2016
208.
Fox
CS
,
Matsushita
K
,
Woodward
M
, et al;
Chronic Kidney Disease Prognosis Consortium
.
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
.
Lancet
2012
;
380
:
1662
1673
209.
Groop
P-H
,
Thomas
MC
,
Moran
JL
, et al;
FinnDiane Study Group
.
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
.
Diabetes
2009
;
58
:
1651
1658
210.
Kramer
HJ
,
Nguyen
QD
,
Curhan
G
,
Hsu
C-Y
.
Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus
.
JAMA
2003
;
289
:
3273
3277
211.
Molitch
ME
,
Steffes
M
,
Sun
W
, et al;
Epidemiology of Diabetes Interventions and Complications Study Group
.
Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study
.
Diabetes Care
2010
;
33
:
1536
1543
212.
Centers for Disease Control and Prevention
.
Chronic kidney disease in the United States, 2021
.
213.
Hemmelgarn
BR
,
James
MT
,
Manns
BJ
, et al
Rates of treated and untreated kidney failure in older vs younger adults
.
JAMA
2012
;
307
:
2507
2715
214.
Wouters
OJ
,
O'Donoghue
DJ
,
Ritchie
J
,
Kanavos
PG
,
Narva
AS
.
Early chronic kidney disease: diagnosis, management and models of care
.
Nat Rev Nephrol
2015
;
11
:
491
502
215.
Yarnoff
BO
,
Hoerger
TJ
,
Simpson
SK
, et al;
Centers for Disease Control and Prevention CKD Initiative
.
The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease
.
BMC Nephrol
2017
;
18
:
85
216.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group
.
KDIGO 2020 clinical practice guidelines for diabetes management in chronic kidney disease
.
Kidney Int
2020
;
98
(
4 Suppl.
)
S1
S115
217.
de Boer
IH
,
Caramori
ML
,
Chan
JCN
, et al
Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence-based advances in monitoring and treatment
.
Kidney Int
2020
;
98
:
839
848
218.
Dagogo-Jack
S
. Complications of diabetes mellitus. In
Scientific American Medicine
.
Singh
AK
, Ed.
Hamilton, Ontario, Canada
,
Decker Intellectual Properties
,
2015
219.
Rossing
P
,
Rossing
K
,
Gaede
P
,
Pedersen
O
,
Parving
H-H
.
Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy
.
Diabetes Care
2006
;
29
:
1024
1030
220.
Naresh
CN
,
Hayen
A
,
Weening
A
,
Craig
JC
,
Chadban
SJ
.
Day-to-day variability in spot urine albumin-creatinine ratio
.
Am J Kidney Dis
2013
;
62
:
1095
1101
221.
Gomes
MB
,
Gonçalves
MF
.
Is there a physiological variability for albumin excretion rate? Study in patients with diabetes type 1 and nondiabetic individuals
.
Clin Chim Acta
2001
;
304
:
117
123
222.
Dagogo-Jack
S
,
Egbuonu
N
,
Edeoga
C
.
Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk
.
Med Princ Pract
2010
;
19
:
167
175
223.
Klahr
S
,
Levey
AS
,
Beck
GJ
, et al;
Modification of Diet in Renal Disease Study Group
.
The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease
.
N Engl J Med
1994
;
330
:
877
884
224.
Murray
DP
,
Young
L
,
Waller
J
, et al
Is dietary protein intake predictive of 1-year mortality in dialysis patients?
Am J Med Sci
2018
;
356
:
234
243
225.
Mills
KT
,
Chen
J
,
Yang
W
, et al;
Chronic Renal Insufficiency Cohort (CRIC) Study Investigators
.
Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease
.
JAMA
2016
;
315
:
2200
2210
226.
Nilsson
E
,
Gasparini
A
,
Arnlov
J
, et al
Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system
.
Int J Cardiol
2017
;
245
:
277
284
227.
Dagogo-Jack
S
. Glycemic control and chronic diabetes complications. In
Therapy for Diabetes Mellitus and Related Disorders
. 6th ed.
Umpierrez
GE
, Ed.
Alexandria, VA
,
American Diabetes Association
,
2014
, p.
668
695
228.
Writing Team for the DCCT/EDIC Research Group
.
Sustained effects of intensive treatment of type 1 diabetes mellitus on the development and progression of diabetic nephropathy
.
JAMA
2003
;
290
:
2159
2167
229.
DCCT/EDIC Research Group
;
de Boer
IH
,
Sun
W
,
Cleary
PA
, et al
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes
.
N Engl J Med
2011
;
365
:
2366
2376
230.
Holman
RR
,
Paul
SK
,
Bethel
MA
,
Neil
HA
,
Matthews
DR
.
Long-term follow-up after tight control of blood pressure in type 2 diabetes
.
N Engl J Med
2008
;
359
:
1565
1576
231.
Long
AN
,
Dagogo-Jack
S
.
The comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection
.
J Clin Hypertens (Greenwich)
2011
;
13
:
244
251
232.
Dagogo-Jack
S
.
Preventing diabetes-related morbidity and mortality in the primary care setting
.
J Natl Med Assoc
2002
;
94
:
549
560
233.
UK Prospective Diabetes Study Group
.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
.
BMJ
1998
;
317
:
703
713
234.
Leehey
DJ
,
Zhang
JH
,
Emanuele
NV
, et al;
VA NEPHRON-D Study Group
.
BP and renal outcomes in diabetic kidney disease: the Veterans Affairs Nephropathy in Diabetes Trial
.
Clin J Am Soc Nephrol
2015
;
10
:
2159
2169
235.
Cushman
WC
,
Evans
GW
,
Byington
RP
, et al;
ACCORD Study Group
.
Effects of intensive blood pressure control in type 2 diabetes mellitus
.
N Engl J Med
2010
;
362
:
1575
1585
236.
Lewis
EJ
,
Hunsicker
LG
,
Bain
RP
,
Rohde
RD
;
The Collaborative Study Group
.
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
.
N Engl J Med
1993
;
329
:
1456
1462
237.
Fried
LF
,
Emanuele
N
,
Zhang
JH
, et al;
VA NEPHRON-D Investigators
.
Combined angiotensin inhibition for the treatment of diabetic nephropathy
.
N Engl J Med
2013
;
369
:
1892
1903
238.
Williams
B
,
MacDonald
TM
,
Morant
S
, et al;
British Hypertension Society's PATHWAY Studies Group
.
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
.
Lancet
2015
;
386
:
2059
2068
239.
Bakris
GL
,
Agarwal
R
,
Chan
JC
, et al;
Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group
.
Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial
.
JAMA
2015
;
314
:
884
894
240.
Moen
MF
,
Zhan
M
,
Hsu
VD
, et al
Frequency of hypoglycemia and its significance in chronic kidney disease
.
Clin J Am Soc Nephrol
2009
;
4
:
1121
1127
241.
Chu
PY
,
Hackstadt
AJ
,
Chipman
J
, et al
Hospitalization for lactic acidosis among patients with reduced kidney function treated with metformin or sulfonylureas
.
Diabetes Care
2020
;
43
:
1462
1470
242.
U.S. Food and Drug Administration
.
FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function
.
243.
Lalau
J-D
,
Kajbaf
F
,
Bennis
Y
,
Hurtel-Lemaire
A-S
,
Belpaire
F
,
De Broe
ME
.
Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4
.
Diabetes Care
2018
;
41
:
547
553
244.
Diabetes Control and Complications Trial Research Group
;
Nathan
DM
,
Genuth
S
,
Lachin
J
, et al
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
.
N Engl J Med
1993
;
329
:
977
986
245.
Murray
P
,
Chune
GW
,
Raghavan
VA
.
Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials
.
Curr Atheroscler Rep
2010
;
12
:
432
439
246.
Zoungas
S
,
Arima
H
,
Gerstein
HC
, et al;
Collaborators on Trials of Lowering Glucose (CONTROL) Group
.
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
.
Lancet Diabetes Endocrinol
2017
;
5
:
431
437
247.
Agrawal
L
,
Azad
N
,
Bahn
GD
, et al;
VADT Study Group
.
Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)
.
Diabetologia
2018
;
61
:
295
299
248.
Zaccardi
F
,
Dhalwani
NN
,
Webb
DR
,
Davies
MJ
,
Khunti
K
.
Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates
.
Diabetologia
2018
;
61
:
1592
1602
249.
Hanefeld
M
,
Duetting
E
,
Bramlage
P
.
Cardiac implications of hypoglycaemia in patients with diabetes: a systematic review
.
Cardiovasc Diabetol
2013
;
12
:
135
250.
Cherney
DZI
,
Perkins
BA
,
Soleymanlou
N
, et al
Renal hemodynamic effect of sodium glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
.
Circulation
2014
;
129
:
587
597
251.
Zelniker
TA
,
Braunwald
E
.
Cardiac and renal effects of sodium–glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review
.
J Am Coll Cardiol
2018
;
72
:
1845
1855
252.
Woods
TC
,
Satou
R
,
Miyata
K
, et al
Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus
.
Am J Nephrol
2019
;
49
:
331
342
253.
Heerspink
HJL
,
Perco
P
,
Mulder
S
, et al
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
.
Diabetologia
2019
;
62
:
1154
1166
254.
Yaribeygi
H
,
Butler
AE
,
Atkin
SL
,
Katsiki
N
,
Sahebkar
A
.
Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways
.
J Cell Physiol
2018
;
234
:
223
230
255.
Arjun
S
,
Bell
RM
.
SGLT2 inhibitors: reviving the sodium-hydrogen exchanger cardioprotection hypothesis?
Cardiovasc Res
2019
;
115
:
1454
1456
256.
Jardine
MJ
,
Mahaffey
KW
,
Neal
B
, et al;
CREDENCE Study Investigators
.
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics
.
Am J Nephrol
2017
;
46
:
462
472
257.
Packer
M
,
Anker
SD
,
Butler
J
, et al;
EMPEROR-Reduced Trial Investigators
.
Cardiovascular and renal outcomes with empagliflozin in heart failure
.
N Engl J Med
2020
;
383
:
1413
1424
258.
Boehringer Ingelheim
.
Invokana (canagliflozin) prescribing information
,
2020
.
260.
Rosenwasser
RF
,
Sultan
S
,
Sutton
D
,
Choksi
R
,
Epstein
BJ
.
SGLT-2 inhibitors and their potential in the treatment of diabetes
.
Diabetes Metab Syndr Obes
2013
;
6
:
453
467
261.
Merck
.
Steglatro (ertugliflozin) prescribing information
.
262.
Zelniker
TA
,
Wiviott
SD
,
Raz
I
, et al
Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus
.
Circulation
2019
;
139
:
2022
2031
263.
.
A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW)
.
Available from https://clinicaltrials.gov/ct2/show/NCT03819153. Accessed 10 March 2021
264.
Bakris
GL
,
Weir
MR
.
Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
Arch Intern Med
2000
;
160
:
685
693
265.
Collard
D
,
Brouwer
TF
,
Peters
RJG
,
Vogt
L
,
van den Born
BH
.
Creatinine rise during blood pressure therapy and the risk of adverse clinical outcomes in patients with type 2 diabetes mellitus
.
Hypertension
2018
;
72
:
1337
1344
266.
James
MT
,
Grams
ME
,
Woodward
M
, et al;
CKD Prognosis Consortium
.
A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury
.
Am J Kidney Dis
2015
;
66
:
602
612
267.
Thakar
CV
,
Christianson
A
,
Himmelfarb
J
,
Leonard
AC
.
Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus
.
Clin J Am Soc Nephrol
2011
;
6
:
2567
2572
268.
Vassalotti
JA
,
Centor
R
,
Turner
BJ
,
Greer
RC
,
Choi
M
,
Sequist
TD
;
National Kidney Foundation Kidney Disease Outcomes Quality Initiative
.
Practical approach to detection and management of chronic kidney disease for the primary care clinician
.
Am J Med
2016
;
129
:
153
162.e7
269.
Guariguata
L
,
Whiting
DR
,
Hambleton
I
,
Beagley
J
,
Linnenkamp
U
,
Shaw
JE
.
Global estimates of diabetes prevalence for 2013 and projections for 2035
.
Diabetes Res Clin Pract
2014
;
103
:
137
149
270.
International Diabetes Federation
.
Diabetes Atlas
. 9th ed.
Brussels, Belgium
,
International Diabetes Federation
,
2019
271.
Liyanage
T
,
Ninomiya
T
,
Jha
V
, et al
Worldwide access to treatment for end-stage kidney disease: a systematic review
.
Lancet
2015
;
385
:
1975
1982
272.
Levin
A
,
Tonelli
M
,
Bonventre
J
, et al;
ISN Global Kidney Health Summit Participants
.
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
.
Lancet
2017
;
390
:
1888
1917
273.
Bakris
GL
,
Molitch
M
.
Microalbuminuria as a risk predictor in diabetes: the continuing saga
.
Diabetes Care
2014
;
37
:
867
875
274.
Patel
RB
,
Colangelo
LA
,
Reis
JP
, et al
Association of longitudinal trajectory of albuminuria in young adulthood with myocardial structure and function in later life: Coronary Artery Risk Development in Young Adults (CARDIA) study
.
JAMA Cardiol
2020
;
5
:
184
192
275.
Bakris
GL
,
Weir
MR
,
Shanifar
S
, et al;
RENAAL Study Group
.
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study
.
Arch Intern Med
2003
;
163
:
1555
1565
276.
Viberti
G
,
Wheeldon
NM
;
Microalbuminuria Reduction With Valsartar (MARVAL) Study Investigators
.
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect
.
Circulation
2002
;
106
:
672
678
277.
American Diabetes Association
.
9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021
.
Diabetes Care
2021
;
44
(
Suppl. 1
):
S111
S124
278.
Hannedouche
T
,
Landais
P
,
Goldfarb
B
, et al
Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure
.
BMJ
1994
;
309
:
833
837
279.
Bakris
GL
,
Copley
JB
,
Vicknair
N
,
Sadler
R
,
Leurgans
S
.
Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
.
Kidney Int
1996
;
50
:
1641
1650
280.
Bakris
GL
,
Mangrum
A
,
Copley
JB
,
Vicknair
N
,
Sadler
R
.
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans
.
Hypertension
1997
;
29
:
744
750
281.
Bakris
G
,
Oshima
M
,
Mahaffey
KW
, et al
Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial
.
Clin J Am Soc Nephrol
2020
;
15
:
1705
1714
282.
Mann
JFE
,
Green
D
,
Jamerson
K
, et al;
ASCEND Study Group
.
Avosentan for overt diabetic nephropathy
.
J Am Soc Nephrol
2010
;
21
:
527
535
283.
Packham
DK
,
Wolfe
R
,
Reutens
AT
, et al;
Collaborative Study Group
.
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy
.
J Am Soc Nephrol
2012
;
23
:
123
130
284.
Tuttle
KR
,
McGill
JB
,
Haney
DJ
,
Lin
TE
,
Anderson
PW
;
PKC-DRS, PKC-DRS 2 Study Groups
.
Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease
.
Clin J Am Soc Nephrol,
2007
;
2
:
631
636
285.
Sharma
K
,
Ix
JH
,
Mathew
AV
, et al
Pirfenidone for diabetic nephropathy
.
J Am Soc Nephrol
2011
;
22
:
1144
1151
286.
Parving
H-H
,
Brenner
BM
,
McMurray
JJV
, et al;
ALTITUDE Investigators
.
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
.
N Engl J Med
2012
;
367
:
2204
2213
287.
de Zeeuw
D
,
Akizawa
T
,
Audhya
P
, et al;
BEACON Trial Investigators
.
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease
.
N Engl J Med
2013
;
369
:
2492
2503
288.
ONTARGET Investigators
;
Yusef
S
,
Teo
KK
,
Pogue
J
, et al
Telmisartan, ramipril, or both in patients at high risk for vascular events
.
N Engl J Med
2008
; 
358
:
1547
1559
289.
Bakris
GL
.
Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors
.
Am J Kidney Dis
2019
;
74
:
573
575
290.
Kraus
BJ
,
Weir
MR
,
Bakris
GL
, et al
Characterization and implications of the initial estimated glomerular filtration rate ‘dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
.
Kidney Int
2021
;
99
:
750
762
291.
Oshima
M
,
Jardine
MJ
,
Agarwal
R
, et al
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
.
Kidney Int
2021
;
99
:
999
1009
292.
Dekkers
CCJ
,
Wheeler
DC
,
Sjöström
CD
,
Stefansson
BV
,
Cain
V
,
Heerspink
HJL
.
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease
.
Nephrol Dial Transplant
2018
;
33
:
2005
2011
293.
Sternlicht
H
,
Bakris
GL
.
Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): more than osmotic diuresis
.
Curr Hypertens Rep
2019
;
21
:
12
294.
Zelniker
TA
,
Braunwald
E
.
Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review
.
J Am Coll Cardiol
2020
;
75
:
422
434
295.
Wilcox
CS
.
Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors
.
Hypertension
2020
;
75
:
894
901
296.
Packer
M
.
Mitigation of the adverse consequences of nutrient excess on the kidney: a unified hypothesis to explain the renoprotective effects of sodium-glucose cotransporter 2 inhibitors
.
Am J Nephrol
2020
;
51
:
289
293
297.
Herat
LY
,
Magno
AL
,
Rudnicka
C
, et al
SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection
.
JACC Basic Transl Sci
2020
;
5
:
169
179
298.
Heerspink
HHJ
,
Perkins
BA
,
Ficthett
DH
,
Husain
M
,
Cherney
DZI
.
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
.
Circulation
2016
;
134
:
752
772
299.
Jardine
MJ
,
Zhou
Z
,
Mchaffey
KW
, et al;
CREDENCE Study Investigators
.
Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial
.
J Am Soc Nephrol
2020
;
31
:
1128
1139
300.
Mayer
GJ
,
Wanner
C
,
Weir
MR
, et al
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics
.
Kidney Int
2019
;
96
:
489
504
301.
Mahaffey
KW
,
Neal
B
,
Perkovic
V
, et al;
CANVAS Program Collaborative Group
.
Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
.
Circulation
2018
;
137
:
323
334
302.
Cannon
CP
,
Pratley
R
,
Dagogo-Jack
S
, et al;
VERTIS CV Investigators
.
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
.
N Engl J Med
2020
;
383
:
1425
1435
303.
Wheeler
DC
,
Stefánsson
BV
,
Jongs
N
, et al;
DAPA-CKD Trial Committees and Investigators
.
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
.
Lancet Diabetes Endocrinol
2021
;
9
:
22
31
304.
Drucker
DJ
,
Nauck
MA
.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
.
Lancet
2006
;
368
:
1696
1705
305.
Tuttle
KR
,
Lakshmanan
MC
,
Rayner
B
, et al
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
.
Lancet Diabetes Endocrinol
2018
;
6
:
605
617
306.
Mann
JFE
,
Muskiet
MHA
.
Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
.
Kidney Int
2021
;
99
:
314
318
307.
Qiu
M
,
Ding
L-L
,
Wei
X-B
,
Liu
S-Y
,
Zhou
H-R
.
Comparative efficacy of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular events in type 2 diabetes: a network meta-analysis
.
J Cardiovasc Pharmacol
2021
;
77
:
34
37
308.
Verma
S
,
McGuire
DK
,
Bain
SC
, et al
Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials
.
Diabetes Obes Metab
2020
;
22
:
2487
2492
309.
Yin
WL
,
Bain
SC
,
Min
T
.
The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes
.
Diabetes Ther
2020
;
11
:
835
844
310.
Marso
SP
,
Daniels
GH
,
Brown-Frandsen
K
, et al;
LEADER Steering Committee; LEADER Trial Investigators
.
Liraglutide and cardiovascular outcomes in type 2 diabetes
.
N Engl J Med
2016
;
375
:
311
322
311.
Holman
RR
,
Bethel
MA
,
Hernandez
AF
.
Once-weekly exenatide and cardiovascular outcomes in type 2 diabetes
.
N Engl J Med
2017
;
377
:
2502
312.
.
Renal effects of treatment with empagliflozin alone or in combination with semaglutide in patients with type 2 diabetes and albuminuria (EmpaSema)
.
Available from https://clinicaltrials.gov/ct2/show/NCT04061200. Accessed 5 March 2021
313.
Hermidorff
MM
,
de Assis
LVM
,
Isoldi
MC
.
Genomic and rapid effects of aldosterone: what we know and do not know thus far
.
Heart Fail Rev
2017
;
22
:
65
89
314.
Sato
A
,
Hayashi
K
,
Naruse
M
,
Saruta
T
.
Effectiveness of aldosterone blockade in patients with diabetic nephropathy
.
Hypertension
2003
;
41
:
64
68
315.
Agarwal
R
,
Kolkhof
P
,
Bakris
G
, et al
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
.
Eur Heart J
2021
;
42
:
152
161
316.
Epstein
M
,
Williams
GH
,
Weinberger
M
, et al
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
.
Clin J Am Soc Nephrol
2006
;
1
:
940
951
317.
Al Dhaybi
O
,
Bakris
GL
.
Non-steroidal mineralocorticoid antagonists: prospects for renoprotection in diabetic kidney disease
.
Diabetes Obes Metab
2020
;
22
(
Suppl. 1
):
69
76
318.
Ruilope
LM
,
Agarwal
R
,
Anker
SD
, et al;
FIGARO-DKD Study Investigators
.
Design and baseline characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial
.
Am J Nephrol
2019
;
50
:
345
356
319.
Filippatos
G
,
Anker
SD
,
Agarwal
R
, et al;
FIDELIO-DKD Investigators
.
Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes
.
Circulation
2021
;
143
:
540
552
320.
Heerspink
HJL
,
Kohan
DE
,
de Zeeuw
D
.
New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction
.
Kidney Int
2021
;
99
:
346
349
321.
Zhao
Y
,
Vanhoutte
PM
,
Leung
SWS
.
Vascular nitric oxide: beyond eNOS
.
J Pharmacol Sci
2015
;
129
:
83
94

The opinions expressed are those of the authors and do not necessarily reflect those of AstraZeneca, Bayer, or the American Diabetes Association. The content was developed by the authors and does not represent the policy or position of the American Diabetes Association, any of its boards or committees, or any of its journals or their editors or editorial boards.

Suggested citation:

Weir MR, Agarwal R, Rossing P, Usman MS, Khan MS, Butler J, Norris KC, Dagogo-Jack S, Naaman SC, Bakris GL. Chronic Kidney Disease and Type 2 Diabetes. Arlington, VA, American Diabetes Association, 2021 ( https://doi.org/10.2337/db2021-01)

Editorial and project management services were provided by Debbie Kendall of Kendall Editorial in Richmond, VA. M.R.W. is supported by National Institutes of Health grants R01 HL-127422, U01 DK-16095-01, U01 DK-106102, and R01 DK-120886. R.A. is supported by National Heart Lung and Blood Institute grant R01 HL126903 and U.S. Veterans Administration grant I01 CX001753. P.R. is supported by Novo Nordisk Foundation grant PROTON Personalized Treatment of Diabetic Nephropathy (NNF14OC0013659).

Dualities of Interest

M.R.W. has served on a clinical trial steering committee for Vifor and on advisory boards for AstraZeneca, Boehringer Ingelheim, Janssen, Merck, Novo Nordisk, and Vifor.

R.A. has received consulting fees from Akebia, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, Diamedica, Merck, Reata, Relypsa, and Sanofi and has received royalties from UpToDate.

P.R.'s institution has received honoraria from his teaching and consultancy activities from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Merck, Merck, Sharp, & Dohme, Mundipharma, Novo Nordisk, Sanofi, and Vifor.

J.B. serves as a consultant for Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squib, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, V-Wave Limited, and Vifor.

K.C.N. has been a consultant to Atlantis Health Care, served on an advisory board for ESRD Network 3, and been a board member of the Forum of ESRD Networks.

S.D.-J. has received research grants from the National Institutes of Health, and his institution has received funding for clinical trials in which he was an investigator from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; he has served as a consultant or advisory board member for AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Merck, and Sanofi; and he is a stock shareholder in Aerami Therapeutics and Jana Care.

G.L.B. has been a consultant to Alnylam, AstraZeneca, Bayer, Ionis, KBP Biosciences, Merck, and Vifor and has served on clinical trial steering committees for Bayer, Novo Nordisk, and Vascular Dynamics.

No other potential conflicts of interest relevant to this compendium were reported.

Author Contributions

All authors researched and wrote their respective sections. Lead author M.R.W. reviewed all content and is the guarantor of this work.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.

Article PDF first page preview

Article PDF first page preview